Lloyd Duplechan joins Ethics Talk to discuss his article: "How High Reliability Can Facilitate Clinical, Organizational, and Public Health Responses to Global Ecological Health Risks.”
Requirements for informed consent are relatively vague and the exceptions are few, so it is in the physician’s best interest to inform patients about proposed treatment options, ascertain that they understand their choices, and secure their consent.
Some commentators say comparative trials of FDA-approved drugs are overburdened by current Common Rule regulations and that researchers should not be required to obtain explicit consent for participation in the most innocuous of these trials.